Heart patients hospitalised with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial presented in a Hot Line session today at ESC Congress 2020.
Michigan Medicine is partnering with the pharmaceutical company AstraZeneca for a Phase 3 clinical trial to test a vaccine against COVID-19. The AZD1222 COVID-19 VACCINE Study will research an investigational vaccine for the prevention of COVID-19, the disease caused by the new coronavirus (SARS-CoV-2).
Johns Hopkins Medicine researchers have added to evidence that a gene responsible for turning off a cell’s natural “suicide” signals may also be the culprit in making breast cancer and melanoma cells resistant to therapies that use the immune system to fight cancer. A summary of the research, conducted with mice and human cells, appeared Aug. 25 in Cell Reports.
The NCCN Oncology Research Program announced plans to develop a program to scientifically evaluate and facilitate clinical trials on the efficacy of decitabine and cedazuridine with research funding provided by Taiho Oncology.
Researchers from Sechenov University together with Russian and Iranian colleagues described currently known approaches to the treatment of SARS-CoV-2 infection.
High school summer students at Brookhaven Lab conduct computational studies, explore inhibitor drugs to disrupt COVID viral proteins that help infectious particles escape from cells.
When the COVID-19 pandemic hit, many students had to rejigger summer plans. Internships they'd expected to be in-person moved to all-virtual formats. For more than 30 students participating in virtual summer programs at the Brookhaven Lab, that disruption presented an opportunity—a chance to engage in research related to the virus responsible for the upheaval.
As countries around the world race to develop a vaccine for SARS-CoV-2, the virus responsible for COVID-19, researchers are working to understand exactly how it causes the myriad of symptoms that seem to linger long after active viral infection.
Structural biology techniques helped researchers target the nuclear receptor-binding SET domain family for the first time; its malfunction is associated with several types of cancer.
DALLAS – Aug. 31, 2020 – Three anticonvulsant drugs commonly used to stop prolonged, potentially deadly seizures each work equally well, according to a national study led by physicians at UT Southwestern. The results provide reassurance to patients who may have drug allergies and to physicians and hospitals that may not have supplies of all three.
Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect will also be effective as a treatment for humans against COVID-19.
New findings from a large European study of patients in 18 countries, including the UK, show that while many patients are able to reduce their risk through taking statins, those at the highest risk of cardiovascular events may benefit from combinations of lipid-lowering therapies.
A new type of breast cancer drug can help halt progression of disease and is not toxic, according to phase 1 clinical trials.
In a study, a team of Penn State researchers report that an algorithm they developed may be able to spot illicit online pharmacies that could be providing customers with substandard medications without their knowledge, among other potential problems.
An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19.
Athletes commonly experience pain in practice and competition. Inadequate or inappropriate pain management in adolescent athletes can lead to a lifetime of consequences including increased risk of opioid misuse. A team physician consensus statement just released by ACSM and 5 other sports medicine organizations shares guidelines to identify and manage pain in athletes ages 10 to 18.
Study is the basis of a new international clinical trial
More than half of patients hospitalized with suspected COVID-19 in Michigan during the state’s peak months received antibiotics soon after they arrive, just in case they had a bacterial infection in addition to the virus, a new study shows. But testing soon showed that 96.5% of them only had the coronavirus, which antibiotics don’t affect.
The use of antibiotics in people with COVID-19 could result in increased resistance to the drugs' benefits among the wider population, a new study suggests.
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.
ROCHESTER, Minn. ― Heart patients who undergo percutaneous coronary intervention (PCI) or stent placement― nonsurgical procedures to improve blood flow to the heart ― are typically prescribed anti-platelet therapy to avoid blood clots that can lead to a heart attack or stroke. New research from the international TAILOR-PCI trial, the largest pharmacogenetics clinical trial in cardiology, suggests that genetic testing could potentially be a useful tool to help select antiplatelet medication. Pharmacogenetics is the use of a patient's genetic makeup in prescribing treatments that are likely to be most successful.
Researchers led by Ludwig Chicago Co-director Ralph Weichselbaum and Ronald Rock of the University of Chicago have identified in preclinical studies a potential drug target for curtailing cancer metastasis.
Splitting one type of cancer drug in half and delivering the pieces separately to cancer cells could reduce life-threatening side effects and protect healthy, non-cancerous cells, a new study suggests.
The human microbiota plays an important role in health and well-being by assisting in digestion, producing nutrients, resisting invading pathogens and regulating metabolism and the immune system.
The timeliness of mail delivery may affect access to medication for many middle-aged and older adults, according to a new analysis of data from a national poll of people aged 50 to 80. Nearly one in four people in this age group said they receive at least one medication by mail, but that percentage rises to 29% when the poll results are limited to people who take at least one prescription medication.
Medication for high blood pressure could improve Covid-19 survival rates and reduce the severity of infection - according to new research from the University of East Anglia.
Mount Sinai scientists have identified two markers of inflammation that reliably predict the severity of COVID-19 cases and likelihood of survival, providing a foundation for a diagnostic platform and therapeutic targets, according to a study published in Nature Medicine in August.
Announcement of University Hospitals plans to participate as a site for the Phase 2/3 global study sponsored by Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) of an investigational vaccine, BNT162b2, against SARS-CoV-2.
In a breakthrough study, researchers at Children’s Hospital of Philadelphia (CHOP) have shown that an enhanced treatment developed in their lab leads to long-term remissions in 80% to 100% of mice with drug-resistant or high-risk solid tumors. The research, which could soon lead to clinical trials, is described in Cancer Research, a journal of the American Association for Cancer Research.
Tweaking the adenovirus spike protein induces a more robust immune reaction for a cancer vaccine against gastric, pancreatic, esophageal and colon malignancies in animal models.
This open-label randomized trial compares the effect of remdesivir (5 or 10 days) compared with standard care on clinical status 11 days after treatment initiation among patients with confirmed SARS-CoV-2 infection hospitalized with moderate pneumonia.
Researchers report in Science Advances that the lipid-based nanoparticles they have engineered, carrying two sets of protein-making instructions, showed in animal studies that they have the potential to function as therapies for two genetic disorders.
Scientists have developed an injectable drug that blocks HIV from entering cells. They say the new drug potentially offers long-lasting protection from the infection with fewer side effects.
Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body’s immune system. The study, which will be published August 27 in the Journal of Experimental Medicine (JEM), suggests that targeting this cellular pathway could help treat the deadly brain cancer glioblastoma, as well as other cancers that are resistant to current forms of immunotherapy.
DALLAS, Aug. 19, 2020 – UT Southwestern Medical Center is the first facility in Dallas and the surrounding region to participate in the international COLCORONA trial. This study is evaluating the therapeutic benefit of colchicine as a treatment to prevent complications and death related to severe cases of COVID-19. Recently diagnosed patients or individuals who are showing symptoms and have a household member diagnosed with COVID-19 over the age of 40 and from Dallas and the surrounding areas can enroll in this free, at-home clinical trial.
September’s edition of SLAS Discovery features the cover article, “Applications of Functional Genomics for Drug Discovery” by Ami M. Kabadi, Ph.D., (Element Genomics), Eoin McDonnell, Ph.D. (Element Genomics), Christopher L. Frank, Ph.D., (Element Genomics), and Lauren Drowley, Ph.D., (UCB Biosciences). The article reviews how functional genomic tools are better able to understand the biological interplay between genes, improving disease modeling and identifying novel drug targets.
Watch live and recorded press conferences at https://www.acs.org/content/acs/en/pressroom/news-room/press-conferences.html. Press conferences will be held Monday, Aug. 17 through Thursday, Aug. 20, 2020
Use of drug-coated balloon angioplasty to treat blocked blood vessels used for hemodialysis offers hope for millions of patients globally
Parkinson’s is a neurological disorder that progressively attacks motor functions, leading to lasting damage in movement and coordination. Researchers studying the primary causes of the disease have focused on mutations of the protein known as leucine-rich repeat kinase 2, or LRRK2.
Irvine, Calif., Aug. 19, 2020 — A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year. The UCI system can go a long way toward the deployment of a vaccine for COVID-19 and toward reopening the economy, as both require widespread testing for the virus and its antibodies.
A drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU), according to findings published in The Lancet Rheumatology.
A first-of-its-kind contraceptive developed at the University of Illinois Chicago has been approved by the U.S. Food and Drug Administration. The new contraceptive, called Phexxi, is a non-hormonal vaginal gel that can be used on-demand to prevent pregnancy.
Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes.
A new study upends the widely held belief that a medication used to treat lymphatic filariasis doesn’t directly target the parasites that cause the disease. The research shows the medication, diethylcarbamazine, temporarily paralyzes the parasites.
Nearly three-quarters of older adults with dementia have filled prescriptions for medicines that act on their brain and nervous system, but aren’t designed for dementia, a new study shows. That’s despite the special risks that such drugs carry for older adults -- and the lack of evidence that they actually ease dementia-related behavior problems.
A press conference on this topic will be held Tuesday, Aug. 19, at 1 p.m. Eastern time online at www.acs.org/fall2020pressconferences.
In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
Systematic reviews and meta-analyses demonstrate that opioids fail to achieve important benefits beyond alternative interventions with less harm.
Patients with early onset psychosis may benefit from treatment for depression, including with anti-depressants alongside other medication, new research shows.
A new study from Lund University and Region Skåne in Sweden indicates that potency-enhancing PDE5 inhibitor drugs have an anti-cancer potential with the ability to improve the prognosis in patients with colorectal cancer. PDE5 inhibitors include a few approved drugs in which sildenafil (Viagra) is the most well-known.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right